Pfizer Inc.
Immunogenic glycoprotein conjugates

Last updated:

Abstract:

The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): (I) wherein: A is a group (C.dbd.X).sub.m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH.sub.2; and when m is 0, B can also be (C.dbd.O); R is a C.sub.2-C.sub.16 alkylene, C.sub.2-C.sub.16 heteroalkylene, NH--C(.dbd.O)--C.sub.2-C.sub.16 alkylene, or NH--C(.dbd.O)--C.sub.2-C.sub.16 heteroalkylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR' where R' is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

6 Feb 2015

Issue date:

2 Jun 2020